HK1070902A1 - Recombinant production of mixtures of antibodies - Google Patents
Recombinant production of mixtures of antibodiesInfo
- Publication number
- HK1070902A1 HK1070902A1 HK05103474.4A HK05103474A HK1070902A1 HK 1070902 A1 HK1070902 A1 HK 1070902A1 HK 05103474 A HK05103474 A HK 05103474A HK 1070902 A1 HK1070902 A1 HK 1070902A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- mixtures
- antibodies
- nucleic acid
- light chain
- host cell
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 150000007523 nucleic acids Chemical group 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39706602P | 2002-07-18 | 2002-07-18 | |
EP02077953 | 2002-07-18 | ||
EPPCT/EP03/50201 | 2003-05-27 | ||
PCT/EP2003/007690 WO2004009618A2 (fr) | 2002-07-18 | 2003-07-15 | Production par recombinaison de melanges d'anticorps |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1070902A1 true HK1070902A1 (en) | 2005-06-30 |
Family
ID=43768900
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK05103474.4A HK1070902A1 (en) | 2002-07-18 | 2005-04-22 | Recombinant production of mixtures of antibodies |
Country Status (15)
Country | Link |
---|---|
US (9) | US7262028B2 (fr) |
EP (2) | EP1523496B1 (fr) |
JP (4) | JP4836451B2 (fr) |
CN (3) | CN101537180B (fr) |
AT (1) | ATE514717T1 (fr) |
AU (2) | AU2003250074B2 (fr) |
CA (3) | CA2872136C (fr) |
CY (1) | CY1111886T1 (fr) |
DK (2) | DK1523496T3 (fr) |
ES (2) | ES2368733T3 (fr) |
HK (1) | HK1070902A1 (fr) |
NZ (1) | NZ537277A (fr) |
PT (2) | PT1523496E (fr) |
SI (1) | SI1523496T1 (fr) |
WO (1) | WO2004009618A2 (fr) |
Families Citing this family (289)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5994128A (en) | 1995-06-15 | 1999-11-30 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US6783980B2 (en) * | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
ATE299938T1 (de) * | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
US20030207346A1 (en) * | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US8236561B2 (en) * | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
US7297680B2 (en) * | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
US20050164386A1 (en) * | 1999-04-15 | 2005-07-28 | Uytdehaag Alphonsus G. | Overexpression of enzymes involved in post-translational protein modifications in human cells |
US6855544B1 (en) * | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
US7521220B2 (en) * | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
US7192759B1 (en) * | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
US7521053B2 (en) * | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7658924B2 (en) * | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
CA2756610C (fr) * | 2001-10-29 | 2015-08-25 | Crucell Holland B.V. | Procedes de production de proteines comportant des glycanes n-lies comprenant des structures (sialyl-) lewis x ou lacdinac |
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
DK1523496T3 (da) | 2002-07-18 | 2011-10-17 | Merus B V | Rekombinant fremstilling af blanding af antistoffer |
EP2290100B1 (fr) * | 2002-11-01 | 2014-02-19 | Iris International, Inc. | Kit pour Immuno-PCR sandwich par déplacement |
GB0230201D0 (en) * | 2002-12-27 | 2003-02-05 | Domantis Ltd | Retargeting |
EA013225B1 (ru) | 2003-01-07 | 2010-04-30 | Симфоген А/С | Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток |
WO2004065611A1 (fr) * | 2003-01-21 | 2004-08-05 | Chugai Seiyaku Kabushiki Kaisha | Procede de selection par criblage d'une chaine legere d'anticorps |
WO2004104046A1 (fr) * | 2003-05-23 | 2004-12-02 | Crucell Holland B.V. | Production d'une igm recombinante dans des cellules per.c6 |
ES2408582T3 (es) | 2003-05-30 | 2013-06-21 | Merus B.V. | Biblioteca de Fab para la preparación de una mezcla de anticuerpos |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
EP1508576A1 (fr) * | 2003-08-20 | 2005-02-23 | Crucell Holland B.V. | Production efficace d'IgA dans des cellules mammifères |
WO2005068622A2 (fr) | 2004-01-20 | 2005-07-28 | Merus B.V. | Melanges de proteines de liaison |
AU2011218688B2 (en) * | 2004-05-27 | 2013-01-10 | Crucell Holland B.V. | Binding molecules capable of neutralizing rabies virus and uses thereof |
EA010785B1 (ru) | 2004-05-27 | 2008-10-30 | Круселл Холланд Б.В. | Связывающие молекулы, способные нейтрализовать вирус бешенства, и их применение |
US7973134B2 (en) | 2004-07-07 | 2011-07-05 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways |
AU2005263334C1 (en) | 2004-07-20 | 2011-01-20 | Symphogen A/S | A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line |
BRPI0513706A (pt) | 2004-07-20 | 2008-05-13 | Symphogen As | anticorpo policlonal recombinante anti-rhesus d e métodos de produção |
US7935790B2 (en) | 2004-10-04 | 2011-05-03 | Cell Singaling Technology, Inc. | Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways |
WO2006137933A2 (fr) * | 2004-11-03 | 2006-12-28 | Leucadia Technologies, Inc. | Microbulles utilisees dans la separation par affinite |
DK1842226T3 (da) | 2004-11-03 | 2010-10-18 | Iris Molecular Diagnostics Inc | Homogen analytpåvisning |
US7807789B2 (en) | 2004-12-21 | 2010-10-05 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in EGFR-signaling pathways |
JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
SI1876236T1 (sl) * | 2005-04-08 | 2014-11-28 | Chugai Seiyaku Kabushiki Kaisha | Protitelo, ki funkcionalno nadomesti faktor viii za koagulacijo krvi |
EP1874821B1 (fr) | 2005-04-26 | 2013-04-17 | Trion Pharma Gmbh | Combinaison d'anticorps et de glucocorticoides destinee au traitement du cancer |
EP1934867A2 (fr) | 2005-08-31 | 2008-06-25 | Cell Signaling Technology, Inc. | Reactifs de detection de phosphorylation proteinique dans des voies de signalisation de leucemie |
US20070111237A1 (en) * | 2005-09-14 | 2007-05-17 | Maurizio Zanetti | Process for identifying antigenized antibodies using ribosome cell free expression system |
AU2012201010B2 (en) * | 2005-10-21 | 2015-01-22 | Genzyme Corporation | Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use |
DK1945666T3 (da) * | 2005-10-21 | 2013-07-01 | Genzyme Corp | Antistoffer med forøget antistofafhængig cellulær cytotoksicitetsaktivitet, fremgangsmåder til fremstilling af disse og anvendelse heraf |
DE102005054628A1 (de) * | 2005-11-16 | 2007-05-24 | Cevec Pharmaceuticals Gmbh | Verfahren zur Herstellung von permanenten humanen Zelllinien |
JP2009518320A (ja) | 2005-12-05 | 2009-05-07 | シュムフォウエン アクティーゼルスカブ | 抗オルトポックスウイルス組換えポリクローナル抗体 |
US20120208824A1 (en) | 2006-01-20 | 2012-08-16 | Cell Signaling Technology, Inc. | ROS Kinase in Lung Cancer |
CA2642706C (fr) * | 2006-02-17 | 2017-08-01 | Atsuo Sekiyama | Indicateur d'une charge biologique et procede permettant de mesurer la charge biologique |
ES2612118T3 (es) | 2006-03-15 | 2017-05-12 | Alexion Pharmaceuticals, Inc. | Tratamiento de pacientes de hemoglobinuria nocturna paroxística mediante un inhibidor del complemento |
EP3345616A1 (fr) | 2006-03-31 | 2018-07-11 | Chugai Seiyaku Kabushiki Kaisha | Procédé de modification d'anticorps pour purifier un anticorps bispécifique |
DK3056568T3 (da) | 2006-03-31 | 2021-11-01 | Chugai Pharmaceutical Co Ltd | Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik |
US7939636B2 (en) | 2006-08-11 | 2011-05-10 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in c-Src signaling pathways |
PL2064325T3 (pl) | 2006-09-01 | 2012-05-31 | Therapeutic Human Polyclonals Inc | Zwiększona ekspresja ludzkiej lub humanizowanej immunoglobuliny u zwierząt transgenicznych innych niż człowiek |
ES2530428T3 (es) | 2006-09-05 | 2015-03-02 | Alexion Pharma Inc | Métodos y composiciones para el tratamiento de neuropatías mediadas por anticuerpos |
JP5410985B2 (ja) | 2006-12-05 | 2014-02-05 | クルセル ホランド ベー ヴェー | 液体抗狂犬病抗体製剤 |
CA2676049C (fr) | 2007-03-01 | 2018-04-10 | Symphogen A/S | Compositions d'anticorps recombinants diriges contre le recepteur du facteur de croissance epidermique |
EP1972639A3 (fr) | 2007-03-07 | 2008-12-03 | Cell Signaling Technology, Inc. | Réactifs pour la détection de la phosphorylation de protéines dans des voies signalant un carcinome |
EP1975184A3 (fr) | 2007-03-26 | 2008-11-26 | Cell Signaling Technology, Inc. | Sites de phosphorylation à sérine ou thréonine |
NL1033696C2 (nl) * | 2007-04-16 | 2008-10-20 | Friesland Brands Bv | Aan melk ontleende antigeen-specifieke antilichamen, werkwijzen voor het bereiden en gebruik ervan. |
US7977462B2 (en) | 2007-04-19 | 2011-07-12 | Cell Signaling Technology, Inc. | Tyrosine phosphorylation sites |
EP2145902A3 (fr) | 2007-04-19 | 2010-09-29 | Peter Hornbeck | Sites de phosphorylation à tyrosine et anticorps spécifiques |
EP1983003A3 (fr) | 2007-04-19 | 2009-03-11 | Peter Hornbeck | Sites de phosphorylation à tyrosine et anticorps spécifiques |
US20090053831A1 (en) | 2007-05-01 | 2009-02-26 | Cell Signaling Technology, Inc. | Tyrosine phosphorylation sites |
NZ581316A (en) * | 2007-05-25 | 2012-02-24 | Symphogen As | Method for manufacturing a recombinant polyclonal protein |
WO2009002380A2 (fr) * | 2007-06-26 | 2008-12-31 | The Trustees Of The University Of Pennsylvania | Isolation d'anticorps anti-desmogléines 1 par expression phagique d'auto-anticorps du pemphigus foliacé |
JP5334319B2 (ja) | 2007-09-26 | 2013-11-06 | 中外製薬株式会社 | Cdrのアミノ酸置換により抗体の等電点を改変する方法 |
EP3741851A1 (fr) | 2007-10-18 | 2020-11-25 | Cell Signaling Technology, Inc. | Translocation et kinase ros mutante dans un carcinome pulmonaire non à petites cellules humaines |
EP2062920A3 (fr) | 2007-11-21 | 2009-06-17 | Peter Hornbeck | Phosphorylation de protéines par des kinases de sérine/thréonine basophiles dans des voies de signalisation de l'insuline |
JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
KR20100122932A (ko) * | 2008-02-21 | 2010-11-23 | 아이리스 인터내셔널 인크. | 전립선 암에 대한 요법 후 재발의 조기 결정 방법 |
EP2098536A1 (fr) | 2008-03-05 | 2009-09-09 | 4-Antibody AG | Isolation et identification de protéines de liaison spécifiques à des antigènes ou à des ligands |
CA2718975A1 (fr) | 2008-04-10 | 2009-10-15 | Cell Signaling Technology, Inc. | Compositions et procedes pour la detection des mutations d'egfr en cas de cancer |
EP2280998A1 (fr) * | 2008-04-23 | 2011-02-09 | Symphogen A/S | Procédés pour fabriquer une protéine polyclonale |
CN102076355B (zh) | 2008-04-29 | 2014-05-07 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
KR20110016958A (ko) | 2008-06-03 | 2011-02-18 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
EP3456190B1 (fr) * | 2008-06-27 | 2021-11-24 | Merus N.V. | Animal murin transgéniques produisant un anticorps |
US8148088B2 (en) | 2008-07-18 | 2012-04-03 | Abgent | Regulation of autophagy pathway phosphorylation and uses thereof |
ES2638579T3 (es) | 2008-08-29 | 2017-10-23 | Symphogen A/S | Composiciones de anticuerpos recombinantes contra el receptor del factor de crecimiento epidérmico |
EP2159291A1 (fr) | 2008-09-01 | 2010-03-03 | Agendia B.V. | Moyen et procédé pour déterminer le pourcentage de cellules tumorales dans un échantillon |
WO2010084197A1 (fr) * | 2009-01-26 | 2010-07-29 | Genmab A/S | Procédés pour produire des mélanges d'anticorps |
ES2533952T3 (es) | 2009-02-09 | 2015-04-16 | Morphosys Ag | Producción de mezclas oligoclonales de inmunoglobulinas en células individuales |
PL2881402T3 (pl) | 2009-02-12 | 2017-10-31 | Cell Signaling Technology Inc | Ekspresja zmutowanej ROS w ludzkim raku wątroby |
US8835610B2 (en) | 2009-03-05 | 2014-09-16 | Abbvie Inc. | IL-17 binding proteins |
ES2708124T3 (es) | 2009-04-27 | 2019-04-08 | Oncomed Pharm Inc | Procedimiento para preparar moléculas heteromultiméricas |
MY164121A (en) | 2009-06-26 | 2017-11-30 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
EP2421357B1 (fr) | 2009-07-08 | 2013-01-23 | Kymab Limited | Modèles d'animaux et molécules thérapeutiques |
MY159837A (en) | 2009-08-29 | 2017-02-15 | Abbvie Inc | Therapeutic dll4 binding proteins |
WO2011069104A2 (fr) | 2009-12-04 | 2011-06-09 | Genentech, Inc. | Anticorps plurispécifiques, analogues d'anticorps, compositions et procédés |
US20120021409A1 (en) * | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
RU2724663C2 (ru) * | 2010-02-08 | 2020-06-25 | Ридженерон Фармасьютикалз, Инк. | Мышь с общей легкой цепью |
EP2542582A4 (fr) | 2010-03-02 | 2013-12-04 | Abbvie Inc | Protéines thérapeutiques de liaison à dll4 |
US9637557B2 (en) | 2010-04-23 | 2017-05-02 | Genentech, Inc. | Production of heteromultimeric proteins |
EP2571532B1 (fr) | 2010-05-14 | 2017-05-03 | Abbvie Inc. | Protéines liant l'il-1 |
UY33492A (es) | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
EP2947151A1 (fr) | 2010-08-02 | 2015-11-25 | Regeneron Pharmaceuticals, Inc. | Protéines de liaison comprenant des domaines vl |
MX341579B (es) | 2010-08-03 | 2016-08-25 | Abbvie Inc * | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
WO2012019132A2 (fr) | 2010-08-06 | 2012-02-09 | Cell Signaling Technology, Inc. | Kinase des lymphomes anaplasiques dans le cancer du rein |
CA2808482C (fr) * | 2010-08-16 | 2021-10-26 | Novimmune S.A. | Procede de production d'anticorps multispecifiques et multivalents |
TW201211252A (en) | 2010-08-26 | 2012-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
SG188328A1 (en) | 2010-09-03 | 2013-04-30 | Stem Centrx Inc | Novel modulators and methods of use |
SI2644698T1 (en) | 2010-11-17 | 2018-05-31 | Chugai Seiyaku Kabushiki Kaisha | MULTISPECIFIC ANTIGEN-TUBULAR MOLECULAR, WITH AN ALTERNATIVE FUNCTION TO THE FACTOR OF BLOOD VIOLATION VIII |
RU2627171C2 (ru) | 2010-12-21 | 2017-08-03 | Эббви Инк. | Il-1 альфа и бета биспецифические иммуноглобулины с двойными вариабельными доменами и их применение |
JP6223829B2 (ja) | 2011-01-03 | 2017-11-01 | エーブイエム・バイオテクノロジー・エルエルシー | 生物学的製剤の個別生成および体細胞を再プログラム化するための方法 |
DE14176593T1 (de) | 2011-02-25 | 2015-03-05 | Regeneron Pharmaceuticals, Inc. | ADAM6 Mäuse |
WO2012122512A1 (fr) | 2011-03-10 | 2012-09-13 | Hco Antibody, Inc. | Production recombinante de mélanges d'anticorps monocaténaires |
US9561274B2 (en) | 2011-06-07 | 2017-02-07 | University Of Hawaii | Treatment and prevention of cancer with HMGB1 antagonists |
US9244074B2 (en) | 2011-06-07 | 2016-01-26 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
SI2739740T1 (sl) * | 2011-08-05 | 2019-12-31 | Regeneron Pharmaceuticals, Inc. | Humanizirane univerzalne lahkoverižne miši |
AU2012311286B2 (en) | 2011-09-19 | 2018-07-26 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
HUE042192T2 (hu) | 2011-09-23 | 2019-06-28 | Oncomed Pharm Inc | VEGF/DLL4-kötõ ágensek és alkalmazásaik |
CA2791109C (fr) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation de molecules de liaison |
MX359384B (es) | 2011-10-11 | 2018-09-25 | Genentech Inc | Conjunto mejorado de anticuerpos bisespecificos. |
SI2627773T1 (sl) | 2011-10-17 | 2017-12-29 | Regeneron Pharmaceuticals, Inc., | Omejena težka veriga imunoglobulinov pri miših |
AR088514A1 (es) | 2011-10-24 | 2014-06-18 | Abbvie Inc | Inmunoligantes biespecificos dirigidos contra tnf |
EP2771360A1 (fr) | 2011-10-24 | 2014-09-03 | AbbVie Inc. | Agents de liaison immunologique dirigés contre la sclérostine |
US9221907B2 (en) | 2011-11-01 | 2015-12-29 | Bionomics Inc. | Anti-GPR49 monoclonal antibodies |
CA2853951A1 (fr) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Anticorps et procedes de traitement du cancer |
EP2773373B1 (fr) | 2011-11-01 | 2018-08-22 | Bionomics, Inc. | Procédés de blocage de la croissance des cellules souches cancéreuses |
AU2012332590B2 (en) | 2011-11-01 | 2016-10-20 | Bionomics, Inc. | Anti-GPR49 antibodies |
EP2793567B1 (fr) | 2011-12-20 | 2019-02-27 | Regeneron Pharmaceuticals, Inc. | Souris à chaînes légères humanisées |
US10745468B2 (en) | 2011-12-22 | 2020-08-18 | Kota Biotherapeutics, Llc | Compositions and methods for modified B cells expressing reassigned biological agents |
US9175072B2 (en) | 2011-12-22 | 2015-11-03 | Elwha Llc | Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen |
US8962315B2 (en) * | 2011-12-22 | 2015-02-24 | Elwha Llc | Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen |
US10233424B2 (en) | 2011-12-22 | 2019-03-19 | Elwha Llc | Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin |
JP2015508994A (ja) | 2011-12-30 | 2015-03-26 | アッヴィ・インコーポレイテッド | Il−13および/またはil−17に対する二重可変ドメイン免疫グロブリン |
US20130171059A1 (en) | 2011-12-30 | 2013-07-04 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
RU2683514C2 (ru) * | 2012-03-06 | 2019-03-28 | Регенерон Фармасьютикалз, Инк. | Мышь с общей легкой цепью |
SI2883449T1 (en) | 2012-03-16 | 2018-05-31 | Regeneron Pharmaceuticals, Inc. | Light-chain modified antibodies with histidine and genetically modified rodents for their production |
US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
CA2865645A1 (fr) | 2012-03-16 | 2013-09-19 | Regeneron Pharmaceuticals, Inc. | Animaux non humains exprimant des sequences d'immunoglobuline sensibles au ph pour le batiment de l'antigene |
EP2825035A1 (fr) | 2012-03-16 | 2015-01-21 | Regeneron Pharmaceuticals, Inc. | Souris produisant des protéines de liaison à l'antigène ayant des caractéristiques de liaison dépendant du ph |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
WO2013158859A1 (fr) | 2012-04-18 | 2013-10-24 | Cell Signaling Technology, Inc. | Egfr et ros1 dans les cancers |
EP3594232A1 (fr) * | 2012-04-20 | 2020-01-15 | Merus N.V. | Procédés et moyens de production de molécules de type ig |
KR102023401B1 (ko) * | 2012-05-10 | 2019-11-04 | 바이오아트라, 엘엘씨 | 다중-특이적 모노클로날 항체 |
NZ717848A (en) | 2012-06-12 | 2019-03-29 | Regeneron Pharma | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
EP2869845B1 (fr) | 2012-07-06 | 2019-08-28 | Genmab B.V. | Protéine dimérique ayant des mutations triples |
EP3632462A1 (fr) | 2012-07-06 | 2020-04-08 | Genmab B.V. | Protéine dimérique ayant des mutations triples |
WO2014011955A2 (fr) | 2012-07-12 | 2014-01-16 | Abbvie, Inc. | Protéines de liaison à il-1 |
CN102851338A (zh) | 2012-07-25 | 2013-01-02 | 苏州康宁杰瑞生物科技有限公司 | 利用电荷排斥作用制备同二聚体蛋白混合物的方法 |
ES2456823B1 (es) * | 2012-09-21 | 2015-01-27 | Consejo Superior De Investigaciones Científicas (Csic) | Método de producción de repertorios complejos de moléculas recombinantes |
EP3470431A1 (fr) | 2012-09-27 | 2019-04-17 | Merus N.V. | Anticorps bispécifiques de type igg comme activateurs de lymphocytes t |
AU2013337775B2 (en) | 2012-11-01 | 2017-03-30 | Abbvie Inc. | Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof |
AU2013339038B2 (en) * | 2012-11-05 | 2017-12-21 | Zenyaku Kogyo Kabushikikaisha | Antibody and antibody composition production method |
JP2016501881A (ja) | 2012-12-04 | 2016-01-21 | アッヴィ・インコーポレイテッド | 血液脳関門(bbb)を透過する二重特異性結合タンパク質 |
US9856319B2 (en) | 2012-12-28 | 2018-01-02 | Abbvie Inc. | Monovalent binding proteins |
US20140219913A1 (en) | 2012-12-28 | 2014-08-07 | Abbvie, Inc. | Dual Specific Binding Proteins Having a Receptor Sequence |
KR20220156667A (ko) | 2013-01-10 | 2022-11-25 | 젠맵 비. 브이 | 인간 IgG1 Fc 영역 변이체 및 그의 용도 |
EP2946016A4 (fr) * | 2013-01-15 | 2016-11-23 | Univ California | Adénovirus et leur utilisation |
CN104994730B (zh) | 2013-02-20 | 2018-12-28 | 瑞泽恩制药公司 | 具有修饰的免疫球蛋白重链序列的非人类动物 |
EP2970437A1 (fr) * | 2013-03-13 | 2016-01-20 | Regeneron Pharmaceuticals, Inc. | Souris à chaine légère classique |
TW201512219A (zh) | 2013-03-15 | 2015-04-01 | Abbvie Inc | 針對IL-1β及/或IL-17之雙特異性結合蛋白 |
US20140271457A1 (en) | 2013-03-15 | 2014-09-18 | Abbvie Inc. | Dual Specific Binding Proteins Directed Against TNF |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
IL290613B1 (en) | 2013-07-05 | 2024-07-01 | Genmab As | CD3 antibodies of human origin or chimeras |
US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
BR112016006197B1 (pt) | 2013-09-27 | 2023-04-11 | Chugai Seiyaku Kabushiki Kaisha | Método para produzir um anticorpo biespecífico de polipeptídeos |
TW201546284A (zh) | 2013-10-01 | 2015-12-16 | Kymab Ltd | 動物模式及治療分子 |
US20150125397A1 (en) | 2013-10-06 | 2015-05-07 | Abbvie Inc. | Dual specific binding proteins directed against immune cell receptors and autoantigens |
JP2016540761A (ja) | 2013-12-02 | 2016-12-28 | アッヴィ・インコーポレイテッド | 変形性関節症を治療するための組成物及び方法 |
BR112016018313A8 (pt) * | 2014-02-10 | 2018-06-12 | Igm Biosciences Inc | Moléculas de ligação multiespecíficas iga |
KR20240042540A (ko) | 2014-02-28 | 2024-04-02 | 메뤼스 엔.페. | ErbB-2와 ErbB-3에 결합하는 항체 |
JP6771385B2 (ja) | 2014-02-28 | 2020-10-21 | メルス ナムローゼ フェンノートシャップ | 二重特異性抗体および医薬組成物 |
ES2762640T3 (es) | 2014-03-21 | 2020-05-25 | Regeneron Pharma | Proteínas VL de unión a antígeno que exhiben diferentes características de unión |
WO2015143414A2 (fr) | 2014-03-21 | 2015-09-24 | Regeneron Pharmaceuticals, Inc. | Animaux non humains qui produisent des protéines de liaison monodomaine |
WO2015153765A1 (fr) | 2014-04-01 | 2015-10-08 | Adimab, Llc | Analogues d'anticorps multispécifiques comprenant une chaîne légère commune, et leur procédés de préparation et leur utilisation |
AU2015240595B2 (en) | 2014-04-03 | 2020-02-27 | Igm Biosciences, Inc. | Modified J-chain |
EP3126397B1 (fr) | 2014-04-04 | 2020-01-29 | Bionomics, Inc. | Anticorps humanisés qui se lient à lgr5 |
KR102603417B1 (ko) | 2014-05-06 | 2023-11-20 | 제넨테크, 인크. | 포유동물 세포를 사용한 이종다량체 단백질의 생산 |
EP3142750B1 (fr) | 2014-05-13 | 2020-07-01 | The Trustees Of The University Of Pennsylvania | Compositions comprenant un virus adéno-associé exprimant des constructions à double anticorps et leurs utilisations |
SG11201610777VA (en) | 2014-07-11 | 2017-01-27 | Genmab As | Antibodies binding axl |
AR101262A1 (es) | 2014-07-26 | 2016-12-07 | Regeneron Pharma | Plataforma de purificación para anticuerpos biespecíficos |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
TWI700300B (zh) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第viii凝血因子(fviii)機能替代活性的物質之抗體 |
TWI701435B (zh) | 2014-09-26 | 2020-08-11 | 日商中外製藥股份有限公司 | 測定fviii的反應性之方法 |
ES2969960T3 (es) | 2014-10-01 | 2024-05-23 | Medimmune Llc | Método para conjugar un polipéptido |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
CN105820251B (zh) * | 2015-01-08 | 2019-10-15 | 江苏康宁杰瑞生物制药有限公司 | 具有共同轻链的双特异性抗体或抗体混合物 |
AU2016209324B2 (en) | 2015-01-20 | 2020-02-27 | Igm Biosciences, Inc. | Tumor necrosis factor (TNF) superfamily receptor binding molecules and uses thereof |
PT3265575T (pt) | 2015-03-04 | 2021-06-16 | Igm Biosciences Inc | Molécula de ligação a cd20 e seus usos |
AU2016232715A1 (en) | 2015-03-19 | 2017-09-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
RS57928B1 (sr) | 2015-07-10 | 2019-01-31 | Merus Nv | Antitela koja vezuju humani cd3 |
EP3730520A1 (fr) | 2015-07-10 | 2020-10-28 | Genmab A/S | Conjugués anticorps-médicament spécifiques d'axl pour le traitement du cancer |
CN114989302A (zh) | 2015-07-15 | 2022-09-02 | 根马布股份公司 | 人源化或嵌合cd3抗体 |
MX2018002493A (es) * | 2015-08-27 | 2018-06-07 | Crystal Bioscience Inc | Animal transgenico para la produccion de anticuerpos que tienen una cadena ligera comun. |
US11639389B2 (en) | 2015-09-30 | 2023-05-02 | Igm Biosciences, Inc. | Binding molecules with modified J-chain |
EP3824903A1 (fr) | 2015-09-30 | 2021-05-26 | IGM Biosciences Inc. | Molécules de liaison à chaîne j modifiée |
PL3365373T3 (pl) | 2015-10-23 | 2021-08-23 | Merus N.V. | Molekuły wiążące, które hamują wzrost nowotworu |
BR112018009312A8 (pt) | 2015-12-28 | 2019-02-26 | Chugai Pharmaceutical Co Ltd | método para promover eficiência de purificação de polipeptídeo contendo região de fc |
RU2018128784A (ru) | 2016-01-27 | 2020-02-27 | МЕДИММЬЮН, ЭлЭлСи | Способы получения антител с заданным профилем гликозилирования |
WO2017165464A1 (fr) | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Molécules multispécifiques et multifonctionnelles et leurs utilisations |
JP2019509322A (ja) | 2016-03-22 | 2019-04-04 | バイオノミクス リミテッド | 抗lgr5モノクローナル抗体の投与 |
CA3025162A1 (fr) | 2016-05-26 | 2017-11-30 | Qilu Puget Sound Biotherapeutics Corporation | Melanges d'anticorps |
UA128304C2 (uk) | 2016-07-14 | 2024-06-05 | Ґенмаб А/С | Мультиспецифічне антитіло до cd40 і cd137 |
EP3509637A4 (fr) | 2016-09-06 | 2020-05-27 | Chugai Seiyaku Kabushiki Kaisha | Procédés d'utilisation d'un anticorps bispécifique qui reconnaît le facteur de coagulation ix et/ou le facteur de coagulation ix activé et le facteur de coagulation x et/ou le facteur de coagulation x activé |
BR112019005895A2 (pt) | 2016-09-23 | 2019-06-11 | Merus N.V. | moléculas de ligação que modulam uma atividade biológica expressa por uma célula |
SG11201903693QA (en) | 2016-11-01 | 2019-05-30 | Genmab Bv | Polypeptide variants and uses thereof |
US11447789B2 (en) | 2016-12-01 | 2022-09-20 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence | Production in plants of ricin antibodies that bind to ricin B chain |
CA3050988A1 (fr) * | 2017-02-02 | 2018-08-09 | Merck Patent Gmbh | Appariement prefere de domaines d'anticorps |
KR20240101717A (ko) | 2017-02-10 | 2024-07-02 | 젠맵 비. 브이 | 폴리펩티드 변이체 및 그의 용도 |
WO2018151820A1 (fr) | 2017-02-16 | 2018-08-23 | Elstar Therapeutics, Inc. | Molécules multifonctionnelles comprenant un ligand trimérique et leurs utilisations |
WO2018162749A1 (fr) | 2017-03-09 | 2018-09-13 | Genmab A/S | Anticorps dirigés contre pd-l1 |
KR20190140944A (ko) | 2017-03-31 | 2019-12-20 | 메뤼스 엔.페. | ErbB-2, ErbB-2/ErbB-3 양성 종양을 가진 개체의 치료를 위한, ErbB-2 및 ErbB-3의 세포외 부분 상의 에피토프에 결합하는 항원-결합 부위를 가진 이중특이적 항체 및 ErbB-2 표적화제 |
CN110650752A (zh) | 2017-03-31 | 2020-01-03 | 美勒斯公司 | 用于治疗具有NRG1融合基因的细胞的ErbB-2和ErbB3结合双特异性抗体 |
JP7330942B2 (ja) | 2017-03-31 | 2023-08-22 | ジェンマブ ホールディング ビー.ブイ. | 二重特異性抗cd37抗体、モノクローナル抗cd37抗体、およびそれらの使用方法 |
MX2019013804A (es) | 2017-05-17 | 2020-02-24 | Merus Nv | Combinacion de un anticuerpo biespecifico de erbb-2/erbb-3 con terapia endocrina para cancer de mama. |
AR111963A1 (es) | 2017-05-26 | 2019-09-04 | Univ California | Método y moléculas |
JP2020522254A (ja) | 2017-05-31 | 2020-07-30 | エルスター セラピューティクス, インコーポレイテッド | 骨髄増殖性白血病(mpl)タンパク質に結合する多特異性分子およびその使用 |
UY37758A (es) | 2017-06-12 | 2019-01-31 | Novartis Ag | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos |
EP3649155A1 (fr) | 2017-07-06 | 2020-05-13 | Merus N.V. | Anticorps bispécifiques anti-pd1 anti-tim3 |
BR112020000209A8 (pt) | 2017-07-06 | 2020-08-11 | Merus Nv | moléculas de ligação que modulam uma atividade biológica expressa por uma célula |
CN117964759A (zh) | 2017-07-06 | 2024-05-03 | 美勒斯公司 | 调节由细胞表达的生物活性的抗体 |
GB201710984D0 (en) * | 2017-07-07 | 2017-08-23 | Kymab Ltd | Cells, vertebrates, populations & methods |
KR20200064062A (ko) | 2017-08-04 | 2020-06-05 | 젠맵 에이/에스 | Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도 |
SG11202001050PA (en) | 2017-08-09 | 2020-03-30 | Merus Nv | Antibodies that bind egfr and cmet |
AU2018338859A1 (en) | 2017-09-29 | 2020-02-06 | Chugai Seiyaku Kabushiki Kaisha | Multispecific antigen-binding molecule having blood coagulation factor VIII (FVIII) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient |
EP3731867A4 (fr) * | 2017-12-19 | 2022-04-06 | Surrozen Operating, Inc. | Anticorps anti-lrp5/6 et leurs procédés d'utilisation |
CN118271444A (zh) | 2017-12-19 | 2024-07-02 | 瑟罗泽恩奥普瑞汀公司 | Wnt替代分子和其用途 |
US20210107988A1 (en) | 2018-01-24 | 2021-04-15 | Genmab B.V. | Polypeptide variants and uses thereof |
TWI804572B (zh) | 2018-02-09 | 2023-06-11 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
MA52152A (fr) | 2018-03-12 | 2021-01-20 | Genmab As | Anticorps |
WO2019178364A2 (fr) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Molécules multifonctionnelles et utilisations associées |
EP3765517A1 (fr) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Molécules multifonctionnelles se liant à calréticuline et utilisations associees |
EP3768707A4 (fr) * | 2018-03-19 | 2022-01-26 | The Invention Science Fund II, LLC | Compositions et procédés pour lymphocytes b modifiés exprimant des agents biologiques réattribués |
KR20200139189A (ko) | 2018-03-30 | 2020-12-11 | 메뤼스 엔.페. | 다가 항체 |
WO2019211472A1 (fr) | 2018-05-03 | 2019-11-07 | Genmab B.V. | Combinaisons de variants d'anticorps et utilisations associées |
US20210371539A1 (en) | 2018-06-22 | 2021-12-02 | Genmab Holding B.V. | Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof |
US20210269509A1 (en) | 2018-06-22 | 2021-09-02 | Genmab A/S | Method for producing a controlled mixture of two or more different antibodies |
DE202019005887U1 (de) | 2018-07-03 | 2023-06-14 | Marengo Therapeutics, Inc. | Anti-TCR-Antikörpermoleküle und Verwendungen davon |
JP7534281B2 (ja) | 2018-07-13 | 2024-08-14 | ジェンマブ エー/エス | Cd38抗体を使用したトロゴサイトーシスを介した治療 |
SG11202012993SA (en) | 2018-07-13 | 2021-02-25 | Genmab As | Variants of cd38 antibody and uses thereof |
MA53812A (fr) | 2018-10-04 | 2021-08-11 | Genmab Holding B V | Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques |
SG11202104300PA (en) | 2018-11-06 | 2021-05-28 | Genmab As | Antibody formulation |
JP7440516B2 (ja) | 2018-12-31 | 2024-02-28 | メルス ナムローゼ フェンノートシャップ | 切断多価多量体 |
BR112021013009A2 (pt) | 2018-12-31 | 2021-09-14 | Merus N.V. | Domínios de ligação mistos |
CA3125380A1 (fr) | 2019-02-18 | 2020-08-27 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Animaux non humains genetiquement modifies ayant un locus d'immunoglobuline humanisee |
AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
CA3130754A1 (fr) | 2019-02-21 | 2020-08-27 | Marengo Therapeutics, Inc. | Molecules multifonctionnelles se liant a des cellules cancereuses associees a des lymphocytes t et leurs utilisations |
WO2020172601A1 (fr) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Molécules multifonctionnelles se liant à la calréticuline et utilisations associées |
GB2598218B (en) | 2019-02-21 | 2024-05-08 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
EP3927745A1 (fr) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Molécules multifonctionnelles se liant à des lymphocytes t et leurs utilisations pour traiter des troubles auto-immuns |
TW202039578A (zh) | 2019-03-29 | 2020-11-01 | 荷蘭商美勒斯公司 | Cd3結合分子 |
TW202102544A (zh) | 2019-04-04 | 2021-01-16 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
SG11202112399PA (en) | 2019-05-09 | 2021-12-30 | Merus Nv | Variant domains for multimerizing proteins and separation thereof |
US20220315661A1 (en) | 2019-05-09 | 2022-10-06 | Genmab B.V. | Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer |
EP3998081A4 (fr) | 2019-07-05 | 2023-07-12 | Ono Pharmaceutical Co., Ltd. | Traitement du cancer hématologique avec une protéine à double spécificité pd-1/cd3 |
WO2021020416A1 (fr) | 2019-07-30 | 2021-02-04 | 小野薬品工業株式会社 | Anticorps bispécifique |
EP3772518A1 (fr) | 2019-08-07 | 2021-02-10 | Merus N.V. | Domaines variables humains modifiés |
GB201912008D0 (en) | 2019-08-21 | 2019-10-02 | Cambridge Entpr Ltd | Antibody |
US20220411529A1 (en) | 2019-11-06 | 2022-12-29 | Genmab B.V. | Antibody variant combinations and uses thereof |
JP7183143B2 (ja) | 2019-12-23 | 2022-12-05 | 日立Astemo株式会社 | エンジンの制御装置 |
IL294181A (en) | 2019-12-24 | 2022-08-01 | Merus Nv | tgf-beta-rii binding proteins |
EP4084821A4 (fr) | 2020-01-03 | 2024-04-24 | Marengo Therapeutics, Inc. | Molécules multifonctionnelles se liant à cd33 et utilisations associées |
BR112022013553A2 (pt) | 2020-01-16 | 2022-09-06 | Genmab As | Composição farmacêutica, anticorpo, e, método para tratar uma doença |
CA3166407A1 (fr) | 2020-01-29 | 2021-08-05 | Merus N.V. | Moyens et procede permettant de moduler les effets d'engagement de cellules immunitaires |
WO2021155916A1 (fr) | 2020-02-04 | 2021-08-12 | BioNTech SE | Traitement impliquant une vaccination d'antigène et des agents de liaison se liant à pd-l1 et cd137 |
TW202200624A (zh) | 2020-03-18 | 2022-01-01 | 丹麥商珍美寶股份有限公司 | 抗體 |
US11707487B2 (en) | 2020-04-13 | 2023-07-25 | Affyimmune Therapeutics, Inc. | EpCAM antibody and CAR-T cells |
WO2021217085A1 (fr) | 2020-04-24 | 2021-10-28 | Marengo Therapeutics, Inc. | Molécules multifonctionnelles se liant à des cellules cancéreuses associées à des lymphocytes t et leurs utilisations |
AR122132A1 (es) | 2020-05-21 | 2022-08-17 | Merus Nv | Métodos y medios para producción de moléculas tipo ig |
CN115667532A (zh) * | 2020-06-02 | 2023-01-31 | 百奥赛图(北京)医药科技股份有限公司 | 具有共有轻链免疫球蛋白基因座的经遗传修饰的非人动物 |
US20230293680A1 (en) | 2020-07-23 | 2023-09-21 | Genmab B.V. | A composition of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma |
US20230272052A1 (en) | 2020-07-31 | 2023-08-31 | CureVac SE | Nucleic acid encoded antibody mixtures |
AU2021322046A1 (en) | 2020-08-06 | 2023-02-02 | BioNTech SE | Binding agents for coronavirus S protein |
AU2021333779A1 (en) | 2020-08-26 | 2023-04-13 | Marengo Therapeutics, Inc. | Methods of detecting TRBC1 or TRBC2 |
AU2021331076A1 (en) | 2020-08-26 | 2023-04-06 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
CN116249718A (zh) | 2020-08-26 | 2023-06-09 | 马伦戈治疗公司 | 结合至钙网蛋白的多功能性分子及其用途 |
MX2023002545A (es) | 2020-09-10 | 2023-03-14 | Genmab As | Anticuerpo biespecifico contra cumulo de diferenciacion 3 (cd3) y cumulo de diferenciacion 20 (cd20) en terapia de combinacion para el tratamiento de linfoma difuso de celulas b grandes. |
MX2023002546A (es) | 2020-09-10 | 2023-03-14 | Genmab As | Anticuerpos biespecificos contra cumulo de diferenciacion 3 (cd3) y contra cumulo de diferenciacion 20 (cd20) para tratar leucemia linfocitica cronica. |
EP4221742A1 (fr) | 2020-10-02 | 2023-08-09 | Genmab A/S | Anticorps pouvant se lier à ror2 et anticorps bispécifiques se liant à ror2 et cd3 |
CN116710486A (zh) | 2020-12-16 | 2023-09-05 | 美勒斯公司 | 用于治疗癌症的多特异性抗体 |
EP4305056A1 (fr) | 2021-03-12 | 2024-01-17 | Genmab A/S | Variants d'anticorps non activateurs |
GB2623199A (en) | 2021-04-08 | 2024-04-10 | Marengo Therapeutics Inc | Multifunctional molecules binding to TCR and uses thereof |
KR20240004949A (ko) | 2021-05-07 | 2024-01-11 | 젠맵 에이/에스 | B7h4 및 cd3에 결합하는 이중특이적 항체를 포함하는 제약 조성물 |
JP2024523438A (ja) | 2021-06-21 | 2024-06-28 | ジェンマブ エー/エス | Cd137結合物質とpd-l1結合物質の組合せ投薬レジメン |
TW202328192A (zh) | 2021-09-06 | 2023-07-16 | 荷蘭商珍美寶公司 | 能結合cd27之抗體、彼之變異體及彼等之用途 |
PE20241175A1 (es) | 2021-10-08 | 2024-05-28 | Genmab As | Anticuerpos de union a cd30 y cd3 |
WO2023146394A1 (fr) | 2022-01-25 | 2023-08-03 | Merus N.V. | Polythérapie pour le traitement du cancer |
WO2023174521A1 (fr) | 2022-03-15 | 2023-09-21 | Genmab A/S | Agents de liaison se liant à epcam et cd137 |
WO2023218046A1 (fr) | 2022-05-12 | 2023-11-16 | Genmab A/S | Agents de liaison capables de se lier à cd27 en polythérapie |
WO2023218051A1 (fr) | 2022-05-12 | 2023-11-16 | Genmab A/S | Agents de liaison capables de se lier à cd27 en polythérapie |
WO2024013723A1 (fr) | 2022-07-15 | 2024-01-18 | Pheon Therapeutics Ltd | Conjugués anticorps-médicament qui se lient à cdcp1 et leurs utilisations |
WO2024094660A1 (fr) | 2022-10-31 | 2024-05-10 | Genmab A/S | Anticorps cd38 et leurs utilisations |
Family Cites Families (209)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5180502A (ja) | 1974-12-28 | 1976-07-14 | Seirei Ind | Tsumejikufurikaeshikiseigyakutenkonsochi |
US4634665A (en) * | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) * | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4599311A (en) * | 1982-08-13 | 1986-07-08 | Kawasaki Glenn H | Glycolytic promotersfor regulated protein expression: protease inhibitor |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
AU600885B2 (en) | 1984-05-25 | 1990-08-30 | Zymogenetics Inc. | Stable DNA constructs |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4868103A (en) * | 1986-02-19 | 1989-09-19 | Enzo Biochem, Inc. | Analyte detection by means of energy transfer |
ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
US4801687A (en) | 1986-10-27 | 1989-01-31 | Bioprobe International, Inc. | Monoclonal antibody purification process using protein A |
US4937190A (en) * | 1987-10-15 | 1990-06-26 | Wisconsin Alumni Research Foundation | Translation enhancer |
US5202238A (en) * | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
FI884924A (fi) | 1987-10-28 | 1989-04-29 | Oncogen | Humanimmuglobulin som producerats med hybrid-dna-teknik. |
ES2035317T5 (es) * | 1987-11-09 | 1998-03-16 | Becton Dickinson Co | Metodo para analizar celulas hematopoyeticas en una muestra. |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
EP1997891A1 (fr) | 1988-09-02 | 2008-12-03 | Dyax Corporation | Production et sélection de protéines de liaison diversifiées recombinantes |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
GB8909218D0 (en) | 1989-04-22 | 1989-06-07 | Medical Res Council | Improvements in or relating to enhancers |
EP0402029B1 (fr) | 1989-06-08 | 1994-01-12 | The Wistar Institute | Anticorps monoclonaux en vue d'un traitement consécutif à une exposition au virus de la rage |
WO1991000906A1 (fr) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Animaux chimeriques et transgeniques pouvant produire des anticorps humains |
US5030002A (en) | 1989-08-11 | 1991-07-09 | Becton, Dickinson And Company | Method and apparatus for sorting particles with a moving catcher tube |
US5959177A (en) † | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US5151504A (en) | 1989-11-17 | 1992-09-29 | E. R. Squibb & Sons, Inc. | Method for purification of monoclonal antibodies |
RU2095414C1 (ru) † | 1989-12-01 | 1997-11-10 | Джен Фарминг Ойроп БВ | Трансген для получения рекомбинантного полипептида в молоке трансгенных коров, способ получения трансгенной коровы (варианты), молоко от трансгенной коровы, пищевой состав |
WO1991010741A1 (fr) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation d'anticorps xenogeniques |
DE4006630A1 (de) | 1990-03-03 | 1991-09-12 | Behringwerke Ag | Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
JPH0568599A (ja) | 1990-07-31 | 1993-03-23 | Wistar Inst | 遺伝子工学的に作られた抗体 |
IE76732B1 (en) * | 1990-08-07 | 1997-11-05 | Becton Dickinson Co | One step test for absolute counts |
US6255458B1 (en) † | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
EP0546073B1 (fr) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production et utilisation des animaux non humains transgeniques capable de produire des anticorps heterologues |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
CA2405246A1 (fr) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Methode d'enrichissement de proteines variantes aux proprietes liantes a lterees |
ES2287206T3 (es) | 1991-03-01 | 2007-12-16 | Dyax Corporation | Proceso para el desarrollo de mini-proteinas de union. |
ES2153358T3 (es) | 1991-03-29 | 2001-03-01 | Genentech Inc | Procedimientos para la seleccion de celulas huespedes recombinantes que expresan altos niveles de una proteina deseada. |
DK1471142T3 (da) | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimere receptor-biblioteker under anvendelse af fagemider |
WO1994004679A1 (fr) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Procede pour fabriquer des anticorps humanises |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
ES2199216T3 (es) | 1991-07-15 | 2004-02-16 | The Wellcome Foundation Limited | Produccion de anticuerpos. |
AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0552108B1 (fr) * | 1992-01-17 | 1999-11-10 | Lakowicz, Joseph R. | Essai fluoro-immunologique impliquant un transfert d'énergie par phase-modulation |
US5667988A (en) * | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
US7067284B1 (en) * | 1992-01-27 | 2006-06-27 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
SE9201984D0 (sv) * | 1992-06-29 | 1992-06-29 | Pharmacia Biosensor Ab | Improvement in optical assays |
AU687010B2 (en) * | 1992-07-17 | 1998-02-19 | Dana-Farber Cancer Institute | Method of intracellular binding of target molecules |
JPH07509137A (ja) | 1992-07-24 | 1995-10-12 | セル ジェネシス,インク. | 異種抗体の生産 |
DE4228162C1 (de) | 1992-08-25 | 1994-01-13 | Rajewsky Klaus Dr | Verfahren zum Ersetzen homologer Genabschnitte aus Säugern in der Keimbahn von nicht-menschlichen Säugern |
EP1167384B1 (fr) | 1992-10-28 | 2006-12-13 | Genentech, Inc. | Récepteur du hVEGF comme antagoniste du VEGF |
CA2149326C (fr) | 1992-11-13 | 2007-04-17 | Mitchell E. Reff | Sequences consensus kozak entierement alterees pour expression par des cellules de mammiferes |
WO1994023046A1 (fr) | 1993-04-07 | 1994-10-13 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Sequence adn agissant comme un element d'isolement de la chromatine pour proteger des genes exprimes de sequences regulatoires a action cis dans des cellules mammaliennes |
US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
CA2168202A1 (fr) | 1993-07-30 | 1995-03-16 | Joseph Dougherty | Transfert genique efficace aboutissant a des lymphocytes primaires |
US5693506A (en) † | 1993-11-16 | 1997-12-02 | The Regents Of The University Of California | Process for protein production in plants |
US5827690A (en) † | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
EP0739412B1 (fr) † | 1993-12-23 | 2002-02-27 | Infigen, Inc. | CELLULES d'ongules, SOUCHES D'EMBRYONS UTILISEES COMME DONNEUSES DE NOYAUX ET PROCEDES DE TRANSFERT DE NOYAUX POUR LA PRODUCTION D'ANIMAUX CHIMERIQUES ET TRANSGENIQUES |
WO1995020401A1 (fr) | 1994-01-31 | 1995-08-03 | Trustees Of Boston University | Banques d'anticorps polyclonaux |
FR2717187B1 (fr) | 1994-03-10 | 1996-05-31 | Transgene Sa | Usage combiné de deux cassettes d'expression pour la production d'une protéine d'intérêt. |
US6080560A (en) † | 1994-07-25 | 2000-06-27 | Monsanto Company | Method for producing antibodies in plant cells |
JPH08116978A (ja) | 1994-10-18 | 1996-05-14 | Nisshinbo Ind Inc | 抗体Fabライブラリーの作製法 |
AU722668B2 (en) * | 1994-12-30 | 2000-08-10 | King's College London | Methods for producing immunoglobulins containing protection proteins in plants and their use |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
US5885827A (en) | 1996-01-23 | 1999-03-23 | The Regents Of The Universtiy Of California | Eukaryotic high rate mutagenesis system |
US6300065B1 (en) | 1996-05-31 | 2001-10-09 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
US6825396B2 (en) | 1996-06-12 | 2004-11-30 | Board Of Trustees Operating Michigan State University | Methods for tissue specific synthesis of protein in eggs of transgenic hens |
JP2001512560A (ja) | 1996-10-08 | 2001-08-21 | ユー―ビスイス ベスローテン フェンノートシャップ | 標的に対し特異的な親和性を有するペプチドおよびタンパク質の選択のための方法および手段 |
GB9621113D0 (en) | 1996-10-10 | 1996-11-27 | Univ Southampton | Transgenic fish |
JP2001505055A (ja) | 1996-12-02 | 2001-04-17 | ウエイク・フオレスト・ユニバーシテイ | Hiv感染の治療としてのhivコレセプターの不活性化 |
JP4215172B2 (ja) | 1996-12-03 | 2009-01-28 | アムジェン フレモント インク. | 複数のV▲下H▼およびV▲下κ▼領域を含むヒトIg遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 |
EP0971946B1 (fr) * | 1997-01-21 | 2006-07-05 | The General Hospital Corporation | Selection de proteines a l'aide de fusions arn-proteine |
WO1998039416A1 (fr) † | 1997-03-06 | 1998-09-11 | Infigen, Inc. | Methode de clonage d'animaux |
CA2283740C (fr) | 1997-03-14 | 2006-06-27 | Idec Pharmaceuticals Corporation | Procede pour integrer des genes a des sites specifiques dans des cellules de mammifere par recombinaison homologue et vecteurs utilises pour la mise en oeuvre de ce procede |
US5830698A (en) * | 1997-03-14 | 1998-11-03 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
US6080912A (en) | 1997-03-20 | 2000-06-27 | Wisconsin Alumni Research Foundation | Methods for creating transgenic animals |
CN1203922A (zh) * | 1997-03-21 | 1999-01-06 | 三共株式会社 | 人源化抗人fas抗体 |
EP1787999B1 (fr) | 1997-04-07 | 2010-08-04 | Genentech, Inc. | Anti-VEGF anticorps |
ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
US20020062010A1 (en) * | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US20030207346A1 (en) * | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
JP2002512624A (ja) | 1997-05-21 | 2002-04-23 | バイオベーション リミテッド | 非免疫原性タンパク質の製造方法 |
GB2345063B (en) | 1997-09-23 | 2002-07-24 | Oxford Biomedica Ltd | Method |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
CN1203178C (zh) | 1997-10-27 | 2005-05-25 | 尤尼利弗公司 | 多价抗原结合蛋白 |
EP0968694B1 (fr) | 1997-11-26 | 2004-05-06 | Mitsubishi Precision Co., Ltd. | Systeme de guidages a informations |
US6074385A (en) | 1998-02-03 | 2000-06-13 | Kiefer Corp. | Hair follicle devitalization by induced heating of magnetically susceptible particles |
IL138579A0 (en) | 1998-03-30 | 2001-10-31 | Res Dev Foundation | Corticotropin releasing factor receptor 1-deficient mice |
US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
CN1241574A (zh) * | 1998-07-02 | 2000-01-19 | 中国人民解放军第四军医大学 | 抗肝癌单克隆抗体HAb25及其单链抗体和双功能抗体 |
GB9823930D0 (en) † | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
JP2002536968A (ja) | 1999-01-29 | 2002-11-05 | イムクローン システムズ インコーポレイティド | Kdrに特異的な抗体およびその使用 |
JP4210036B2 (ja) | 1999-04-15 | 2009-01-14 | クルセル ホランド ベー ヴェー | ヒト細胞における組み換え蛋白質の生産 |
EP2067788B1 (fr) | 1999-05-18 | 2015-07-22 | Dyax Corp. | Bibliothèque des fragments Fab et méthodes d'utilisation |
US6472147B1 (en) | 1999-05-25 | 2002-10-29 | The Scripps Research Institute | Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
PT1189641E (pt) | 1999-06-25 | 2009-11-04 | Genentech Inc | Anticorpos anti-erbb2 humanizados e tratamento com anticorpos anti-erbb2 |
WO2001019394A2 (fr) | 1999-09-15 | 2001-03-22 | Therapeutic Human Polyclonals, Inc. | Immunotherapie utilisant des preparations d'anticorps polyclonaux sensiblement humains purifies a partir d'oiseaux fabriques par genie genetique |
US6180357B1 (en) | 1999-10-08 | 2001-01-30 | Arius Research, Inc. | Individualized patient-specific anti-cancer antibodies |
AU7676300A (en) * | 1999-10-12 | 2001-04-23 | Cambridge Antibody Technology Limited | Human anti-adipocyte monoclonal antibodies and their use |
WO2001032901A1 (fr) | 1999-11-01 | 2001-05-10 | Chiron Corporation | Vecteurs d'expression, systemes de transfection et leur procede d'utilisation |
GB9928787D0 (en) * | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
DE60033455T2 (de) | 1999-12-27 | 2007-11-29 | Crucell Holland B.V. | Menschlischer monoklonaler Antikörper gegen Ep-CAM und dessen Verwendung in Krebstherapie |
AU2001245358A1 (en) † | 2000-02-29 | 2001-09-12 | Auburn University | Production of antibodies in transgenic plastids |
JP2004506408A (ja) | 2000-04-26 | 2004-03-04 | イルーシス セラポーティクス,インコーポレーテッド | 二重特異性分子及びその用途 |
US6890532B2 (en) | 2000-05-16 | 2005-05-10 | Thomas Jefferson University | Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods |
KR20080074231A (ko) | 2000-06-29 | 2008-08-12 | 아보트 러보러터리즈 | 이중 특이성 항체 및 이의 제조 및 사용 방법 |
CN1334343A (zh) * | 2000-07-14 | 2002-02-06 | 中国医学科学院肿瘤医院肿瘤研究所 | 抑制肿瘤生长的新抗体、其衍生物及其应用 |
EP1184458A1 (fr) † | 2000-08-28 | 2002-03-06 | U-BISys B.V. | Epitopes de CD46 exprimés différentiellement, des molécules protéiniques capables de s'y lier, et leurs utilisations |
EP1188771A1 (fr) | 2000-09-15 | 2002-03-20 | U-BISys B.V. | Bibliothèques de fragments variables des chaines lourdes humaines au format fonctionnel |
US7737258B2 (en) | 2000-10-18 | 2010-06-15 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
FR2817875B1 (fr) | 2000-12-07 | 2005-03-18 | Technopharm | Procede de preparation d'un anticorps monoclonal humain, de fragments de celui-ci ou d'anticorps comprenant de tels fragments, les anticorps ainsi obtenus et leur utilisation |
JP2004525624A (ja) | 2001-01-25 | 2004-08-26 | エボルバ バイオテック アクティーゼルスカブ | 細胞コレクションのライブラリー |
WO2002074969A2 (fr) | 2001-01-26 | 2002-09-26 | University Of Lausanne | Regions se liant a la matrice nucleaire (mar) et procedes d'utilisation de celles-ci |
WO2002096948A2 (fr) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Anticorps tetravalents modifies et procedes d'utilisation |
JP2005508608A (ja) | 2001-03-22 | 2005-04-07 | アボット ゲーエムベーハー ウント カンパニー カーゲー | 問題遺伝子に対して特異的な抗体を発現するトランスジェニック動物及びその使用 |
GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
US7595378B2 (en) * | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
US7247301B2 (en) * | 2001-06-13 | 2007-07-24 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
AU2002345421B2 (en) | 2001-06-15 | 2006-11-16 | Crucell Holland B.V. | Chimaeric phages |
DE60237282D1 (de) | 2001-06-28 | 2010-09-23 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
DE60236331D1 (de) | 2001-07-04 | 2010-06-17 | Chromagenics Bv | DNS-Sequenzen mit Anti-Repressor-Aktivität |
ATE557040T1 (de) | 2001-08-21 | 2012-05-15 | Univ Jefferson | Rekombinante antikörper sowie zusammensetzungen und verfahren zu deren herstellung und verwendung |
US20030077739A1 (en) | 2001-08-27 | 2003-04-24 | Genentech, Inc. | System for antibody expression and assembly |
JP2005535282A (ja) | 2001-11-16 | 2005-11-24 | アイデック ファーマシューティカルズ コーポレイション | 抗体のポリシストロニック発現 |
CA2468878A1 (fr) | 2001-11-30 | 2003-06-05 | Crucell Holland B.V. | Conjugue de ciblage de cellule de presentation de l'antigene, cellule de presentation de l'antigene mise en contact avec ledit conjugue, leur utilisation pour la vaccination ou entant que medicament et leurs procedes de production ou de generation |
CA2468583C (fr) | 2001-11-30 | 2012-05-01 | C. Roger Mackenzie | Complexes de liaisons multimeres d'auto-assemblage derives de membres de la famille des toxines ab5 |
US20050037427A1 (en) | 2001-12-10 | 2005-02-17 | Erwin Houtzager | Structure for presenting desired peptide sequences |
US20030215914A1 (en) | 2001-12-10 | 2003-11-20 | Erwin Houtzager | Structure for presenting desired peptide sequences |
US7244592B2 (en) * | 2002-03-07 | 2007-07-17 | Dyax Corp. | Ligand screening and discovery |
GB2387030A (en) | 2002-03-26 | 2003-10-01 | Thales Plc | Compensation of mutual coupling in array antenna systems |
JP4753578B2 (ja) | 2002-06-03 | 2011-08-24 | ジェネンテック, インコーポレイテッド | 合成抗体ファージライブラリー |
ITGE20020049A1 (it) | 2002-06-05 | 2003-12-05 | Ali Spa | Dispositivo a pistone per la erogazione di quantitativi dosati di sostanze pastose, quali i gelati, applicabile alle macchine per la loro fa |
CA2489475C (fr) | 2002-06-14 | 2011-03-29 | Chromagenics B.V. | Procede permettant la production simultanee de plusieurs proteines; vecteurs et cellules utilises dans ce procede |
WO2003106674A2 (fr) | 2002-06-14 | 2003-12-24 | Chromagenics B.V. | Moyens et procedes de regulation de l'expression genique |
AU2002368062A1 (en) | 2002-06-26 | 2004-01-19 | Imclone Systems Incorporated | Bispecific antibodies that bind to vegf receptors |
US20080241166A1 (en) | 2002-06-28 | 2008-10-02 | Domantis Limited | Ligands that bind a receptor |
WO2004007860A1 (fr) | 2002-07-10 | 2004-01-22 | Agostino Di Trapani | Element de construction |
DK1523496T3 (da) | 2002-07-18 | 2011-10-17 | Merus B V | Rekombinant fremstilling af blanding af antistoffer |
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
EA013225B1 (ru) | 2003-01-07 | 2010-04-30 | Симфоген А/С | Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток |
EP1439234A1 (fr) | 2003-01-08 | 2004-07-21 | ARTEMIS Pharmaceuticals GmbH | Transgénèse ciblée utilisant le locus 26 |
ES2408582T3 (es) | 2003-05-30 | 2013-06-21 | Merus B.V. | Biblioteca de Fab para la preparación de una mezcla de anticuerpos |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
CA2529001A1 (fr) | 2003-06-10 | 2004-12-16 | Catchmabs B.V. | Nouveaux peptides de liaison, leurs procedes de production et d'utilisation |
WO2005012360A2 (fr) | 2003-07-22 | 2005-02-10 | Crucell Holland B.V. | Molecules de liaison dirigees contre le coronavirus du syndrome respiratoire aigu severe et applications de celles-ci |
JP4712724B2 (ja) | 2003-12-23 | 2011-06-29 | クルセル ホランド ベー ヴェー | CD1aに対するヒト結合分子 |
WO2005068622A2 (fr) | 2004-01-20 | 2005-07-28 | Merus B.V. | Melanges de proteines de liaison |
EA010785B1 (ru) | 2004-05-27 | 2008-10-30 | Круселл Холланд Б.В. | Связывающие молекулы, способные нейтрализовать вирус бешенства, и их применение |
US7728114B2 (en) | 2004-06-03 | 2010-06-01 | Novimmune S.A. | Anti-CD3 antibodies and methods of use thereof |
WO2006028936A2 (fr) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Molecules heteromultimeriques |
JP4487068B2 (ja) | 2004-10-12 | 2010-06-23 | 国立大学法人 岡山大学 | 細胞の遺伝子変異機能の制御による変異タンパク質の作製方法 |
EP2279749B1 (fr) | 2004-10-12 | 2015-06-10 | Crucell Holland B.V. | Molecule de liaison pour la détection de lam |
WO2006051091A1 (fr) | 2004-11-11 | 2006-05-18 | Crucell Holland B.V. | Compositions contre le coronavirus du sras et utilisations de ces compositions |
JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
CA2604440A1 (fr) | 2005-04-29 | 2006-11-09 | Inserm (Institut De La Sante Et De La Recherche Medicale) | Animaux transgeniques et procedes de fabrication d'anticorps recombines |
EP1879921B1 (fr) | 2005-05-12 | 2011-04-27 | Crucell Holland B.V. | Molécules de liaison spécifiques de cellule hote capables de neutraliser des virus et leurs utilisations |
US20090130652A1 (en) | 2005-06-23 | 2009-05-21 | Crucell Holland B.V. | Optimization of West Nile Virus Antibodies |
US8642513B2 (en) | 2005-09-15 | 2014-02-04 | Crucell Holland B.V. | Method for preparing immunoglobulin libraries |
PL1999154T3 (pl) | 2006-03-24 | 2013-03-29 | Merck Patent Gmbh | Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe |
WO2007117410A2 (fr) | 2006-03-31 | 2007-10-18 | Medarex, Inc. | Animaux transgéniques exprimant des anticorps chimériques destinés à être utilisés pour la préparation d'anticorps humains |
ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
WO2007141274A2 (fr) | 2006-06-06 | 2007-12-13 | Crucell Holland B.V. | Molécules de liaison humaines présentant une activité bactéricide contre les staphylocoques et leurs utilisations |
KR20200058579A (ko) | 2006-06-06 | 2020-05-27 | 얀센 백신스 앤드 프리벤션 비.브이. | 장내구균에 대한 사멸활성을 갖는 인간결합분자 및 그것의 용도 |
WO2007147901A1 (fr) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production d'anticorps bispécifiques |
EP2059532B1 (fr) | 2006-09-07 | 2012-12-26 | Crucell Holland B.V. | Molécules de liaison humaines capables de neutraliser le virus de la grippe h5n1 et leurs utilisations |
MX2009003393A (es) | 2006-10-02 | 2009-05-11 | Regeneron Pharma | Anticuerpos humanos de alta afinidad para el receptor de il-4 humano. |
US8290739B2 (en) | 2006-10-20 | 2012-10-16 | Amfit, Inc. | Method for determining relative mobility of regions of an object |
NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
WO2008119353A1 (fr) | 2007-03-29 | 2008-10-09 | Genmab A/S | Anticorps bispécifiques et procédés de production de ceux-ci |
ITMI20071522A1 (it) | 2007-07-27 | 2009-01-28 | Areta Internat S R L | Vaccino idiotipico |
EP3124497B1 (fr) | 2007-09-14 | 2020-04-15 | Adimab, LLC | Bibliothèques d'anticorps synthétiques conçus de façon rationnelle et leurs utilisations |
US8536310B2 (en) | 2007-10-17 | 2013-09-17 | Arca Biopharma, Inc. | Antibodies to CLL-1 |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
HUE028536T2 (en) | 2008-01-07 | 2016-12-28 | Amgen Inc | Method for producing antibody to FC heterodimer molecules using electrostatic control effects |
CA2715043C (fr) | 2008-02-05 | 2021-02-16 | Zymeworks Inc. | Procedes de determination de residus correles dans une proteine ou autre biopolymere mettant en oeuvre la dynamique moleculaire |
EP3456190B1 (fr) | 2008-06-27 | 2021-11-24 | Merus N.V. | Animal murin transgéniques produisant un anticorps |
WO2010084197A1 (fr) | 2009-01-26 | 2010-07-29 | Genmab A/S | Procédés pour produire des mélanges d'anticorps |
ES2708124T3 (es) | 2009-04-27 | 2019-04-08 | Oncomed Pharm Inc | Procedimiento para preparar moléculas heteromultiméricas |
NZ596032A (en) | 2009-05-11 | 2013-09-27 | Crucell Holland Bv | Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof |
MY164121A (en) | 2009-06-26 | 2017-11-30 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
RU2724663C2 (ru) | 2010-02-08 | 2020-06-25 | Ридженерон Фармасьютикалз, Инк. | Мышь с общей легкой цепью |
US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
WO2011143545A1 (fr) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Protéines hétérodimériques et leurs procédés de production et de purification |
EP2603526A1 (fr) | 2010-08-13 | 2013-06-19 | Medimmune Limited | Polypeptides monomères comprenant des régions du variant fc et procédés d'utilisation de ceux-ci |
CA2808482C (fr) | 2010-08-16 | 2021-10-26 | Novimmune S.A. | Procede de production d'anticorps multispecifiques et multivalents |
EP2635607B1 (fr) | 2010-11-05 | 2019-09-04 | Zymeworks Inc. | Conception d'anticorps hétérodimérique stable ayant des mutations dans le domaine fc |
DE14176593T1 (de) | 2011-02-25 | 2015-03-05 | Regeneron Pharmaceuticals, Inc. | ADAM6 Mäuse |
EA028804B1 (ru) | 2011-03-25 | 2018-01-31 | Гленмарк Фармасьютикалс С.А. | Гетеродимерные иммуноглобулины |
JP2013004215A (ja) | 2011-06-14 | 2013-01-07 | Hitachi Ltd | リチウムイオン二次電池 |
JP2016184957A (ja) | 2012-02-09 | 2016-10-20 | シャープ株式会社 | 情報処理装置及び情報処理方法 |
EP3594232A1 (fr) | 2012-04-20 | 2020-01-15 | Merus N.V. | Procédés et moyens de production de molécules de type ig |
EP3470431A1 (fr) | 2012-09-27 | 2019-04-17 | Merus N.V. | Anticorps bispécifiques de type igg comme activateurs de lymphocytes t |
-
2003
- 2003-07-15 DK DK03764997.7T patent/DK1523496T3/da active
- 2003-07-15 WO PCT/EP2003/007690 patent/WO2004009618A2/fr active Application Filing
- 2003-07-15 CA CA2872136A patent/CA2872136C/fr not_active Expired - Lifetime
- 2003-07-15 ES ES03764997T patent/ES2368733T3/es not_active Expired - Lifetime
- 2003-07-15 ES ES10186063T patent/ES2442615T5/es not_active Expired - Lifetime
- 2003-07-15 AT AT03764997T patent/ATE514717T1/de active
- 2003-07-15 AU AU2003250074A patent/AU2003250074B2/en not_active Expired
- 2003-07-15 PT PT03764997T patent/PT1523496E/pt unknown
- 2003-07-15 EP EP03764997A patent/EP1523496B1/fr not_active Expired - Lifetime
- 2003-07-15 DK DK10186063.3T patent/DK2314629T4/da active
- 2003-07-15 NZ NZ537277A patent/NZ537277A/en not_active IP Right Cessation
- 2003-07-15 CA CA2965865A patent/CA2965865C/fr not_active Expired - Lifetime
- 2003-07-15 CN CN200910132819.2A patent/CN101537180B/zh not_active Expired - Lifetime
- 2003-07-15 JP JP2004522465A patent/JP4836451B2/ja not_active Expired - Lifetime
- 2003-07-15 CN CN201610051739.4A patent/CN105884893A/zh active Pending
- 2003-07-15 CN CNB038170779A patent/CN100480260C/zh not_active Expired - Lifetime
- 2003-07-15 CA CA2492377A patent/CA2492377C/fr not_active Expired - Lifetime
- 2003-07-15 SI SI200332045T patent/SI1523496T1/sl unknown
- 2003-07-15 EP EP10186063.3A patent/EP2314629B2/fr not_active Expired - Lifetime
- 2003-07-15 PT PT101860633T patent/PT2314629E/pt unknown
-
2005
- 2005-01-18 US US11/039,767 patent/US7262028B2/en not_active Expired - Lifetime
- 2005-04-22 HK HK05103474.4A patent/HK1070902A1/xx not_active IP Right Cessation
-
2006
- 2006-11-06 US US11/593,279 patent/US7429486B2/en not_active Expired - Lifetime
- 2006-11-06 US US11/593,280 patent/US7932360B2/en active Active
-
2008
- 2008-07-29 US US12/221,021 patent/US7927834B2/en not_active Expired - Lifetime
-
2010
- 2010-12-02 AU AU2010249150A patent/AU2010249150B9/en not_active Expired
-
2011
- 2011-03-04 US US12/932,719 patent/US9303081B2/en not_active Expired - Lifetime
- 2011-05-30 JP JP2011121054A patent/JP6049239B2/ja not_active Expired - Lifetime
- 2011-09-23 CY CY20111100924T patent/CY1111886T1/el unknown
-
2013
- 2013-03-12 US US13/795,637 patent/US20130243773A1/en not_active Abandoned
-
2014
- 2014-07-03 JP JP2014137927A patent/JP6166693B2/ja not_active Expired - Fee Related
-
2016
- 2016-04-04 US US15/090,505 patent/US10934571B2/en not_active Expired - Lifetime
- 2016-09-21 JP JP2016184803A patent/JP2016220696A/ja active Pending
-
2017
- 2017-12-14 US US15/842,303 patent/US20180094289A1/en not_active Abandoned
- 2017-12-27 US US15/855,258 patent/US20180112247A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1070902A1 (en) | Recombinant production of mixtures of antibodies | |
GB0129105D0 (en) | Expression control using variable intergenic sequences | |
EP1652925A4 (fr) | Production d'igm par cellules transformees et procedes de quantification de cette derniere | |
IL188094A0 (en) | Il-1?? binding antibodies and fragments thereof | |
DE60042969D1 (de) | Zubereitungen und methoden zur verwendung in rekombinatorischem klonen von nukleinsäuren | |
WO2002016436A3 (fr) | ANTICORPS DE LA IL-1β HUMAINE | |
NZ594968A (en) | Humanized c-kit antibody | |
WO2006113546A3 (fr) | Anticorps monoclonaux recombines et antigenes correspondants contre les cancers du colon et du pancreas | |
HK1071898A1 (en) | Recombinant antibodies, and compositions and methods for making and using the same | |
TW200635946A (en) | Binding proteins specific for human matriptase | |
DK1450847T3 (da) | Apo2-ligand/TRAIL-formuleringer og anvendelser deraf | |
IL169804A (en) | 254p1d6b proteins, nucleic acids encoding the same, processes for producing the same, antibodies binding thereto and uses thereof | |
WO2003022868A3 (fr) | Proteines pouvant se lier avec des metaux et procedes associes | |
WO2005047325A3 (fr) | Sequences d'immunoglobuline de singes | |
WO2006013462A3 (fr) | Facteurs de croissance nsg28, nsg30, et nsg32 | |
WO2003040301A3 (fr) | Proteines de progression du cycle cellulaire | |
WO2002044366A3 (fr) | Nouvelles proteines humaines specifiques de la retine c7orf9, c12orf7, mpp4 et f379 | |
ATE426033T1 (de) | Promoter sequenzen aus moos und dessen verwendung | |
WO2002077023A3 (fr) | Un nouveau composant aval essentiel du chemin de signalisation des aptères | |
WO2004058938A3 (fr) | Sequences de l-pbe canine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PE | Patent expired |
Effective date: 20230714 |